Synergistic anti-tumor activity of Nimotuzumab in combination with Trastuzumab in HER2-positive breast cancer

Biochemical and Biophysical Research Communications

Volumn 489, Issue 4, 2017, Pages 523-527

  Yang, Yun ^a   Guo, Rui ^a   Tian, Xiaoting ^b   Zhang, Ziheng ^a   Zhang, Pengfei ^a   Li, Changzheng ^a   Feng, Zhiwei ^a  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Breast cancer; ERK1 2; Nimotuzumab; NRF2; ROS; Trastuzumab

Indexed keywords

ACTIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NIMOTUZUMAB; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; IN VITRO STUDY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; NUDE MOUSE; PATHOLOGY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; REACTIVE OXYGEN SPECIES; RECEPTOR, ERBB-2; STRUCTURE-ACTIVITY RELATIONSHIP; TRASTUZUMAB;

EID: 85020165398     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2017.06.001     Document Type: Article

References (19)

1. Ribe, A.R., Laurberg, T., Laursen, T.M., Charles, M., Vedsted, P., Vestergaard, M., Ten-year mortality after a breast cancer diagnosis in women with severe mental illness: a Danish population-based cohort study. PLoS One, 11, 2016, e0158013.
2. Dawood, S., Broglio, K., Buzdar, A.U., Hortobagyi, G.N., Giordano, S.H., Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J. Clin. Oncol. 28 (2010), 92–98.
3. Hudis, C.A., Trastuzumab–mechanism of action and use in clinical practice. N. Engl. J. Med. 357 (2007), 39–51.
4. Zhang, S., Huang, W.C., Li, P., Guo, H., Poh, S.B., Brady, S.W., Xiong, Y., Tseng, L.M., Li, S.H., Ding, Z., Sahin, A.A., Esteva, F.J., Hortobagyi, G.N., Yu, D., Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat. Med. 17 (2011), 461–469.
5. Baselga, J., Gelmon, K.A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V.A., Ross, G.A., Fumoleau, P., Gianni, L., Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 28 (2010), 1138–1144.
6. Hicks, M., Macrae, E.R., Abdel-Rasoul, M., Layman, R., Friedman, S., Querry, J., Lustberg, M., Ramaswamy, B., Mrozek, E., Shapiro, C., Wesolowski, R., Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials. Oncologist 20 (2015), 337–343.
7. Li, B., Meng, Y., Zheng, L., Zhang, X., Tong, Q., Tan, W., Hu, S., Li, H., Chen, Y., Song, J., Zhang, G., Zhao, L., Zhang, D., Hou, S., Qian, W., Guo, Y., Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization. Cancer Res. 73 (2013), 6471–6483.
8. Kang, H.J., Yi, Y.W., Hong, Y.B., Kim, H.J., Jang, Y.J., Seong, Y.S., Bae, I., HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction. Sci. Rep., 4, 2014, 7201.
9. Manandhar, S., Choi, B.H., Jung, K.A., Ryoo, I.G., Song, M., Kang, S.J., Choi, H.G., Kim, J.A., Park, P.H., Kwak, M.K., NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity. Free Radic. Biol. Med. 52 (2012), 1773–1785.
10. Gauron, C., Rampon, C., Bouzaffour, M., Ipendey, E., Teillon, J., Volovitch, M., Vriz, S., Sustained production of ROS triggers compensatory proliferation and is required for regeneration to proceed. Sci. Rep., 3, 2013, 2084.
11. Kang, K.W., Ryu, J.H., Kim, S.G., The essential role of phosphatidylinositol 3-kinase and of p38 mitogen-activated protein kinase activation in the antioxidant response element-mediated rGSTA2 induction by decreased glutathione in H4IIE hepatoma cells. Mol. Pharmacol. 58 (2000), 1017–1025.
12. Zipper, L.M., Mulcahy, R.T., Inhibition of ERK and p38 MAP kinases inhibits binding of Nrf2 and induction of GCS genes. Biochem. Biophys. Res. Commun. 278 (2000), 484–492.
13. Khalil, H.S., Langdon, S.P., Goltsov, A., Soininen, T., Harrison, D.J., Bown, J., Deeni, Y.Y., A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells. Oncotarget 7 (2016), 75874–75901.
14. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., McGuire, W.L., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987), 177–182.
15. Seshacharyulu, P., Ponnusamy, M.P., Haridas, D., Jain, M., Ganti, A.K., Batra, S.K., Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets 16 (2012), 15–31.
16. Yang, Y., Guo, Q., Xia, M., Li, Y., Peng, X., Liu, T., Tong, X., Xu, J., Guo, H., Qian, W., Hou, S., Dai, J., Wang, H., Liu, R., Guo, Y., Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency. MAbs, 2015, 0.
17. Ramakrishnan, M.S., Eswaraiah, A., Crombet, T., Piedra, P., Saurez, G., Iyer, H., Arvind, A.S., Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 1 (2009), 41–48.
18. Khalil, H.S., Langdon, S.P., Kankia, I.H., Bown, J., Deeni, Y.Y., NRF2 regulates HER2 and HER3 signaling pathway to modulate sensitivity to targeted immunotherapies. Oxid. Med. Cell Longev., 2016, 2016, 4148791.
19. Liu, L.Z., Hu, X.W., Xia, C., He, J., Zhou, Q., Shi, X., Fang, J., Jiang, B.H., Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radic. Biol. Med. 41 (2006), 1521–1533.